Médecine

Paramédical

Autres domaines


Suscribirse

Prevalence of Aspirin and Clopidogrel Resistance Among Patients With and Without Drug-Eluting Stent Thrombosis - 12/08/11

Doi : 10.1016/j.amjcard.2009.04.015 
Tina L. Pinto Slottow, MD a, Laurent Bonello, MD a, Rekha Gavini, BS a, Patricia Beauzile, BS a, Steven J. Sushinsky, BS a, Mickey Scheinowitz, PhD a, Kimberly Kaneshige, BS a, Zhenyi Xue, MS a, Rebecca Torguson, MPH a, Udaya Tantry, PhD b, Augusto D. Pichard, MD a, Lowell F. Satler, MD a, William O. Suddath, MD a, Kenneth Kent, MD, PhD a, Paul Gurbel, MD b, Ron Waksman, MD a,
a Division of Cardiology, Washington Hospital Center, Washington, District of Columbia 
b Sinai Center for Thrombosis Research, Baltimore, Maryland 

Corresponding author: Tel: (202) 877-2812; fax: (202) 877-2715

Resumen

Drug-eluting stent (DES) thrombosis has a multifactorial etiology. Variable responsiveness to antiplatelet therapy likely contributes to its pathogenesis. We aimed to determine whether patients who had experienced DES thrombosis compared with a cohort of patients who had not would exhibit greater platelet reactivity and a greater prevalence of aspirin and clopidogrel resistance. The effect of aspirin and clopidogrel on platelet reactivity was determined after angiographically proven DES thrombosis in 26 patients and in 21 patients who had not experienced stent thrombosis (ST) ≥18 months after DES implantation. Aspirin effect was assessed using the VerifyNow Aspirin Assay, and the effect of clopidogrel was assessed using the VerifyNow P2Y12 Assay and vasodilator-stimulated phosphoprotein phosphorylation (VASP-P). Aspirin resistance was present in 23% of patients with ST and 5% of controls (p = NS). Clopidogrel resistance was present in 40% of patients with ST and 14% of controls using the P2Y12 assay (p = 0.02) and 90% of patients with ST and 67% of controls using the VASP-P assay (p = NS). Mean aspirin reaction units were significantly greater among all patients with ST and those with early ST compared with controls (477 ± 89 vs 429 ± 58, p = 0.04; and 485 ± 84 vs 429 ± 58, p = 0.02, respectively). Mean P2Y12 reaction units were significantly greater among patients with early ST compared with controls (265 ± 102 vs 184 ± 76, p = 0.01). The results of the VASP-P assay did not correlate with the presence of ST. In conclusion, patients who experienced DES thrombosis demonstrated significantly greater rates of clopidogrel resistance as determined by P2Y12 reaction units, but not VASP-P, compared with patients without DES thrombosis. Aspirin reaction units were significantly greater in the DES thrombosis population. Point-of-care testing with the VerifyNow Aspirin and P2Y12 Assays has the potential to identify patients at increased risk of ST, particularly early ST, after DES deployment.

El texto completo de este artículo está disponible en PDF.

Esquema


© 2009  Elsevier Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 104 - N° 4

P. 525-530 - août 2009 Regresar al número
Artículo precedente Artículo precedente
  • Comparison of Usefulness of Simvastatin 20 mg Versus 80 mg in Preventing Contrast-Induced Nephropathy in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
  • Jia Xinwei, Fu Xianghua, Zhang Jing, Gu Xinshun, Xue Ling, Fan Weize, Hao Guozhen, Jiang Yunfa, Wu Weili, Li Shiqiang
| Artículo siguiente Artículo siguiente
  • Impact of Different Re-stenting Strategies on Expansion of a Drug-Eluting Stent Implanted to Treat Bare-Metal Stent Restenosis
  • Łukasz Kalińczuk, Marcin Demkow, Gary S. Mintz, Krzysztof Cedro, Artur Dębski, Michał Ciszewski, Andrzej Ciszewski, Mariusz Kruk, Maciej Karcz, Grzegorz Warmiński, Jerzy Pręgowski, Zbigniew Chmielak, Adam Witkowski, Barbara Lubiszewska, Witold Rużyłło

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.